These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

786 related items for PubMed ID: 32748163

  • 1. Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphoma.
    Pinczés LI, Szabó R, Illés Á, Földeák D, Piukovics K, Szomor Á, Gopcsa L, Miltényi Z.
    Ann Hematol; 2020 Oct; 99(10):2385-2392. PubMed ID: 32748163
    [Abstract] [Full Text] [Related]

  • 2. Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma.
    Picardi M, Della Pepa R, Giordano C, Pugliese N, Mortaruolo C, Trastulli F, Rascato MG, Cappuccio I, Raimondo M, Memoli M, Monteverde M, Mascolo M, Pane F.
    Blood Adv; 2019 May 14; 3(9):1546-1552. PubMed ID: 31088808
    [Abstract] [Full Text] [Related]

  • 3. Brentuximab vedotin in association with bendamustine in refractory or multiple relapsed Hodgkin lymphoma. A retrospective real-world study.
    Iannitto E, Romano A, Scalzulli PR, Bonanno V, Scalone R, Chiarenza A, Pirosa MC, Caruso AL, Minoia C, Mantuano S, De Santis G, Salerno M, Crescimanno A, Porretto F, Li Gioi F, Ricciuti G, Greco A, Pavone E, Guarini A, Tarantini G, Mannina D, Consoli U, Cascavilla N, Di Raimondo F, Musso M.
    Eur J Haematol; 2020 Jun 14; 104(6):581-587. PubMed ID: 32107795
    [Abstract] [Full Text] [Related]

  • 4. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial.
    O'Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, Falchi L, Marchi E, Turenne I, Lichtenstein R, Rojas C, Francescone M, Schwartz L, Cheng B, Savage KJ, Villa D, Crump M, Prica A, Kukreti V, Cremers S, Connors JM, Kuruvilla J.
    Lancet Oncol; 2018 Feb 14; 19(2):257-266. PubMed ID: 29276022
    [Abstract] [Full Text] [Related]

  • 5. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma.
    LaCasce AS, Bociek RG, Sawas A, Caimi P, Agura E, Matous J, Ansell SM, Crosswell HE, Islas-Ohlmayer M, Behler C, Cheung E, Forero-Torres A, Vose J, O'Connor OA, Josephson N, Wang Y, Advani R.
    Blood; 2018 Jul 05; 132(1):40-48. PubMed ID: 29703778
    [Abstract] [Full Text] [Related]

  • 6. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
    Taçyıldız N, Tanyıldız HG, Ünal E, Dinçaslan H, Asarcıklı F, Aksoy BA, Vatansever G, Yavuz G.
    Turk J Pediatr; 2019 Jul 05; 61(5):671-676. PubMed ID: 32104998
    [Abstract] [Full Text] [Related]

  • 7. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study.
    Kuruvilla J, Ramchandren R, Santoro A, Paszkiewicz-Kozik E, Gasiorowski R, Johnson NA, Fogliatto LM, Goncalves I, de Oliveira JSR, Buccheri V, Perini GF, Goldschmidt N, Kriachok I, Dickinson M, Komarnicki M, McDonald A, Ozcan M, Sekiguchi N, Zhu Y, Nahar A, Marinello P, Zinzani PL, KEYNOTE-204 investigators.
    Lancet Oncol; 2021 Apr 05; 22(4):512-524. PubMed ID: 33721562
    [Abstract] [Full Text] [Related]

  • 8. Treatment with brentuximab vedotin plus bendamustine in unselected patients with CD30-positive aggressive lymphomas.
    Wagner SM, Melchardt T, Egle A, Magnes T, Skrabs C, Staber P, Simonitsch-Klupp I, Panny M, Lehner B, Greil R, Keil F, Jäger U, Sillaber C.
    Eur J Haematol; 2020 Mar 05; 104(3):251-258. PubMed ID: 31838747
    [Abstract] [Full Text] [Related]

  • 9. Brentuximab vedotin and bendamustine: an effective salvage therapy for relapsed or refractory Hodgkin lymphoma patients.
    Uncu Ulu B, Dal MS, Yönal Hindilerden İ, Akay OM, Mehtap Ö, Büyükkurt N, Hindilerden F, Güneş AK, Yiğenoğlu TN, Başcı S, Kızıl Çakar M, Yanardağ Açık D, Korkmaz S, Ulaş T, Özet G, Ferhanoğlu B, Nalçacı M, Altuntaş F.
    J Chemother; 2022 May 05; 34(3):190-198. PubMed ID: 34514960
    [Abstract] [Full Text] [Related]

  • 10. Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group).
    Garcia-Sanz R, Sureda A, de la Cruz F, Canales M, Gonzalez AP, Pinana JL, Rodriguez A, Gutierrez A, Domingo-Domenech E, Sanchez-Gonzalez B, Rodriguez G, Lopez J, Moreno M, Rodriguez-Salazar MJ, Jimenez-Cabrera S, Caballero MD, Martinez C.
    Ann Oncol; 2019 Apr 01; 30(4):612-620. PubMed ID: 30657848
    [Abstract] [Full Text] [Related]

  • 11. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
    Pavone V, Mele A, Carlino D, Specchia G, Gaudio F, Perrone T, Mazza P, Palazzo G, Guarini A, Loseto G, Eleonora P, Cascavilla N, Scalzulli P, Melpignano A, Quintana G, Di Renzo N, Tarantini G, Capalbo S.
    Ann Hematol; 2018 Oct 01; 97(10):1817-1824. PubMed ID: 30054707
    [Abstract] [Full Text] [Related]

  • 12. Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.
    Herrera AF, Palmer J, Martin P, Armenian S, Tsai NC, Kennedy N, Sahebi F, Cao T, Budde LE, Mei M, Siddiqi T, Popplewell L, Rosen ST, Kwak LW, Nademanee A, Forman SJ, Chen R.
    Ann Oncol; 2018 Mar 01; 29(3):724-730. PubMed ID: 29272364
    [Abstract] [Full Text] [Related]

  • 13. Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
    Lynch RC, Cassaday RD, Smith SD, Fromm JR, Cowan AJ, Warren EH, Shadman MS, Shustov A, Till BG, Ujjani CS, Libby EN, Philip M, Coye H, Martino CN, Bhark SL, Morris K, Rasmussen H, Behnia S, Voutsinas J, Gopal AK.
    Lancet Haematol; 2021 Aug 01; 8(8):e562-e571. PubMed ID: 34329577
    [Abstract] [Full Text] [Related]

  • 14. Brentuximab Vedotin and Bendamustine Produce Long-Term Clinical Benefit in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma: A Multicenter Real-Life Experience.
    Moretti M, Liberati AM, Rigacci L, Puccini B, Pulsoni A, Gini G, Galieni P, Fabbri A, Cantonetti M, Pavone V, Bolis S, Botto B, Renzi D, Falchi L.
    Clin Lymphoma Myeloma Leuk; 2022 Mar 01; 22(3):198-204. PubMed ID: 34690088
    [Abstract] [Full Text] [Related]

  • 15. Brentuximab vedotin consolidation after autologous stem cell transplantation for Hodgkin lymphoma: A Fondazione Italiana Linfomi real-life experience.
    Massaro F, Pavone V, Stefani PM, Botto B, Pulsoni A, Patti C, Cantonetti M, Visentin A, Scalzulli PR, Rossi A, Galimberti S, Cimminiello M, Gini G, Musso M, Sorio M, Arcari A, Zilioli VR, Luppi M, Mannina D, Fabbri A, Pietrantuono G, Annibali O, Tafuri A, Prete E, Mulè A, Barbolini E, Marcheselli L, Luminari S, Merli F.
    Hematol Oncol; 2022 Feb 01; 40(1):31-39. PubMed ID: 34694649
    [Abstract] [Full Text] [Related]

  • 16. Results of a Multicenter Phase II Trial of Brentuximab Vedotin as Second-Line Therapy before Autologous Transplantation in Relapsed/Refractory Hodgkin Lymphoma.
    Chen R, Palmer JM, Martin P, Tsai N, Kim Y, Chen BT, Popplewell L, Siddiqi T, Thomas SH, Mott M, Sahebi F, Armenian S, Leonard J, Nademanee A, Forman SJ.
    Biol Blood Marrow Transplant; 2015 Dec 01; 21(12):2136-2140. PubMed ID: 26211987
    [Abstract] [Full Text] [Related]

  • 17. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Moskowitz CH, Nademanee A, Masszi T, Agura E, Holowiecki J, Abidi MH, Chen AI, Stiff P, Gianni AM, Carella A, Osmanov D, Bachanova V, Sweetenham J, Sureda A, Huebner D, Sievers EL, Chi A, Larsen EK, Hunder NN, Walewski J, AETHERA Study Group.
    Lancet; 2015 May 09; 385(9980):1853-62. PubMed ID: 25796459
    [Abstract] [Full Text] [Related]

  • 18. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
    Zinzani PL, Vitolo U, Viviani S, Corradini P, Motta G, Tani M, Cascavilla N, Hohaus S, Merli F, Argnani L, Broccoli A.
    Clin Lymphoma Myeloma Leuk; 2015 Jul 09; 15(7):404-8. PubMed ID: 25840816
    [Abstract] [Full Text] [Related]

  • 19. Bendamustine can be a bridge to allogeneic transplantation in relapsed Hodgkin lymphoma refractory to brentuximab vedotin.
    Howell M, Gibb A, Radford J, Linton K.
    Br J Haematol; 2017 Dec 09; 179(5):841-843. PubMed ID: 27447404
    [No Abstract] [Full Text] [Related]

  • 20. First salvage treatment with bendamustine and brentuximab vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi.
    Broccoli A, Argnani L, Botto B, Corradini P, Pinto A, Re A, Vitolo U, Fanti S, Stefoni V, Zinzani PL, Fondazione Italiana Linfomi ONLUS.
    Blood Cancer J; 2019 Dec 11; 9(12):100. PubMed ID: 31827067
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.